文献速递前列腺癌

帕博利珠单抗单药治疗微卫星高度不稳定和/或肿瘤突变负荷高的转移性去势抵抗性前列腺癌的真实世界经验:结局分析

A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-02-10

回顾性分析2018至2023年在Mayo Clinic接受帕博利珠单抗单药治疗至少3周期的22例MSI-H或TMB-H的mCRPC患者,ORR为50%(完全缓解27.3%,部分缓解22.7%)。TMB 10-14.9、15-24.9和≥25 mut/Mb组的mPFS分别为2.1个月、未达到和未达到(p=0.0003),mOS分别为5.1个月、20.5个月和未达到。无合并MSI-H或CDK12的TMB-H患者(n=6)无一例缓解,而MSI-H患者(n=12)的ORR为75%。作者认为MSI-H驱动帕博利珠单抗疗效,TMB-H但无合并MSI-H或CDK12时应考虑替代治疗策略。

要点

  • 22例MSI-H或TMB-H的mCRPC患者接受帕博利珠单抗单药治疗,ORR为50%。
  • TMB 10-14.9、15-24.9和≥25 mut/Mb组的mPFS分别为2.1个月、未达到和未达到(p=0.0003)。
  • 无合并MSI-H或CDK12的TMB-H患者(n=6)无一例缓解,MSI-H患者(n=12)ORR为75%。

核心结论

  • 作者认为MSI-H驱动帕博利珠单抗在mCRPC中的疗效,且随着TMB升高生存结局更好。
  • 作者建议当TMB-H但无合并MSI-H或CDK12时,临床医生应考虑替代治疗策略。

研究设计与样本

  • 回顾性分析2018至2023年在Mayo Clinic接受帕博利珠单抗单药治疗至少3周期的mCRPC患者,共22例,均因MSI-H或TMB-H指征用药。
  • 所有患者均行下一代测序(NGS),其中组织活检11例、液体活检10例。
  • 疗效按RECIST v1.1标准评估客观缓解率(ORR)、中位无进展生存期(mPFS)和总生存期(mOS)。

主要发现

  • 总体ORR为50%,其中完全缓解27.3%、部分缓解22.7%。
  • TMB 10-14.9 mut/Mb组(n=4)、TMB 15-24.9 mut/Mb组(n=6)和TMB ≥25 mut/Mb组(n=10)的mPFS分别为2.1个月、未达到和未达到(p=0.0003)。
  • 上述三组的mOS分别为5.1个月、20.5个月和未达到。
  • 无合并MSI-H或CDK12的TMB-H患者(n=6)无一例缓解,仅1例疾病稳定;MSI-H患者(n=12)的ORR为75%。
  • 完全缓解患者中常见ATRX和PTCH1等免疫治疗应答相关突变。

临床怎么用

  • 作者认为MSI-H驱动帕博利珠单抗在mCRPC中的疗效,且随着TMB升高生存结局更好。
  • 作者建议当TMB-H但无合并MSI-H或CDK12时,临床医生应考虑替代治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of pembrolizumab monotherapy in metastatic castration-resistant prostate cancer patients (mCRPC) when stratified by MSI-H and/or TMB-H is poorly defined. Additionally, outcomes based on sequencing source (i.e., tissue or liquid biopsy) have not been well described. We sought to assess outcomes of pembrolizumab monotherapy in patients with mCRPC and compare efficacy based on MSI-H and/or TMB-H when identified by tissue or liquid biopsy. METHODS: A retrospective analysis was performed of mCRPC patients treated at Mayo Clinic with pembrolizumab monotherapy between 2018 and 2023. Objective response rates (ORR), median progression-free survival (mPFS), and overall survival (mOS), were determined by RECIST v1.1 criteria. RESULTS: Twenty-two patients with mCRPC received pembrolizumab monotherapy for at least 3 cycles for a MSI-H or TMB-H indication. All patients had next generation sequencing (NGS) performed via tissue (n = 11) or liquid (n = 10) biopsy source. The ORR was 50% (27.3% complete response and 22.7% had partial response). The mPFS for TMB 10-14.9 mut/Mb (n = 4), TMB 15-24.9 mut/Mb (n = 6), and TMB ≥ 25 mut/Mb (n = 10) was 2.1, not reached (NR), and NR, respectively (p = 0.0003). The mOS for these same groups was 5.1 months, 20.5 months, and not reached, respectively. Among patients with TMB-H without co-occurring MSI-H or CDK12 (n = 6), none experienced a response and only one patient had stable disease compared to patients with MSI-H (n = 12) for whom the ORR was 75%. Immunotherapy responsive alterations such as ATRX and PTCH1 mutations were frequently noticed among patients who had complete response (CR). CONCLUSIONS: Our hypothesis-generating study suggests that MSI-H drives the efficacy of pembrolizumab in mCRPC with better survival outcomes as TMB increases. Clinicians should consider alternative treatment strategies for advanced prostate cancer when TMB-H is present without co-occurring MSI-H or CDK12.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Mosalem O, Tan W, Bryce AH, et al. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis. Prostate Cancer Prostatic Dis. 2024. PMID: 38341460. doi:10.1038/s41391-024-00799-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。